← Patent-cliff monitor small molecule UPTRAVI SELEXIPAG
Loss of exclusivity June 2037 latest FDA-listed patent expiry
Company Actelion → See this company's full patent-cliff portfolio Drug detail Brand name UPTRAVI Active ingredient SELEXIPAG Strength 1.6MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2015 Marketing status RX
Listed patents Patent Expires Type 10828298*PED June 2037 — 10821108*PED June 2037 — 10828298 December 2036 product 10821108 December 2036 product 8791122*PED February 2031 — 9284280*PED December 2030 — 8791122 August 2030 substance, product 9284280 June 2030 use U-1831 9173881*PED February 2030 — 9173881 August 2029 use U-1798 7205302*PED April 2027 — 7205302 October 2026 substance, product
Regulatory exclusivity Code Expires PED November 2029 NPP May 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.